Lonza's Sfr865m block covered in 40 minutes

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Lonza's Sfr865m block covered in 40 minutes

Lonza_CEO_AP_230x150
Stefan Borgas, CEO of Lonza, speaks at a press conference in Zurich, Switzerland Monday July 11, 2011. Swiss speciality chemicals maker Lonza says it has made an offer to buy U.S. rival Arch Chemicals for US dlrs 1.4 billion ( 1 billion euro). Lonza says it is offering 47.20 in cash for each share of the Connecticut-based company that produces bacteria-killing chemicals. The Basel, Switzerland-based supplier of chemicals to the pharmaceutical industry says this represents a 36.7 percent premium on Arch Chemicals' average share price over the past month. The deal announced Monday July 11, 2011 is subject to antitrust approval. (AP Photo/Keystone/Steffen Schmidt) GERMANY OUT - AUSTRIA OUT | Steffen Schmidt/AP

Lonza, the Swiss pharmaceuticals company, completed a 9.4% capital increase through a Sfr865m accelerated bookbuild on Tuesday night led by UBS and Bank of America Merrill Lynch, the first step in a two-pronged move to raise Sfr3.3bn for an acquisition.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article